|
VXUS·Vanguard Total International Stock ETF
Updating price...
Market Closed (Overnight)
High
$86.83
Open
$85.81
Market Cap
-
52W High
—
Low
$85.50
P. Close
$85.87
P/E
-
52W Low
—
Technical Score (1D)
36
SELL
News Sentiment
65
BULLISH
What's happening to VXUS today?
VXUS is currently buoyed by a cascade of positive signals across its top holdings, beginning with AZN’s Phase‑III COPD trial data that cut exacerbations by roughly 30 % and underpins a forecast of more than $5 billion in peak annual sales for the new biologic, a clear earnings‑boosting catalyst for the ETF’s oncology exposure. ASML’s announcement to lift EUV production to 110 machines by 2028, a 37.5 % jump over 2027 levels, signals a robust demand for advanced lithography and reinforces the semiconductor theme that underpins VXUS’s technology weighting. TSMC’s move of its 2‑nanometer process from lab to commercial use in MediaTek’s Dimensity 9600 Pro provides the first tangible revenue path for the next‑generation node and validates the company’s ramp‑up strategy, adding a short‑term earnings lift for the ETF’s chip sector. Meanwhile, BABA’s issuance of $10.2 billion of equity to fund AI data‑center expansion introduces a potential volatility factor for VXUS’s consumer‑technology exposure, raising questions about dilution versus long‑term AI upside. Collectively, these developments highlight a convergence of pipeline breakthroughs, capacity expansion, and AI‑driven growth that could lift sector earnings over the next 1–10 trading days. The AI infrastructure push may create short‑term price swings while also feeding demand for semiconductors, creating a second‑order effect that could amplify ASML and TSMC’s upside. Uncertainty remains around BABA’s equity‑funded AI spend, as analysts differ on whether the dilution will outweigh the long‑term upside. Traders should keep an eye on AZN’s Q1 2027 FDA decision, ASML’s assembly‑capacity execution, TSMC’s 2‑nm commercial rollout, and BABA’s equity‑funded AI spend as the next key data points.
